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Objective To estimate risks of major congenital anomaly (MCA)
among children of mothers prescribed antidepressants during
early pregnancy or diagnosed with depression but without
antidepressant prescriptions.
Design Population-based cohort study.
Setting Linked UK maternal–child primary care records.
Population A total of 349 127 singletons liveborn between 1990
and 2009.
Methods Odds ratios adjusted for maternal sociodemographics
and comorbidities (aORs) were calculated for MCAs, comparing
women with first-trimester selective serotonin reuptake inhibitors
(SSRIs) or tricyclic antidepressants (TCAs) and women with
diagnosed but unmedicated depression, or women without
diagnosed depression.
Main outcome measures Fourteen system-specific MCA groups
classified according to the European Surveillance of Congenital
Anomalies and five specific heart anomaly groups.
Results Absolute risks of MCA were 2.7% (95% confidence
interval, 95% CI, 2.6–2.8%) in children of mothers without
diagnosed depression, 2.8% (95% CI 2.5–3.2%) in children of
mothers with unmedicated depression, and 2.7% (95% CI 2.2–
3.2%) and 3.1% (95% CI 2.2–4.1%) in children of mothers with
SSRIs or TCAs, respectively. Compared with women without
depression, MCA overall was not associated with unmedicated
depression (aOR 1.07, 95% CI 0.96–1.18), SSRIs (aOR 1.01,
95% CI 0.88–1.17), or TCAs (aOR 1.09, 95% CI 0.87–1.38).
Paroxetine was associated with increased heart anomalies
(absolute risk 1.4% in the exposed group compared with 0.8% in
women without depression; aOR 1.78, 95% CI 1.09–2.88), which
decreased marginally when compared with women with
diagnosed but unmedicated depression (aOR 1.67, 95% CI
1.00–2.80).
Conclusions Overall MCA risk did not increase with maternal
depression or with antidepressant prescriptions. Paroxetine was
associated with increases of heart anomalies, although this could
represent a chance finding from a large number of comparisons
undertaken.
Keywords Antidepressants, congenital anomaly, depression,
SSRIs, TCAs.
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Introduction
Antenatal depression is estimated to affect 8–11% of
women in high-income countries,1 and the proportion of
pregnant women prescribed antidepressants has increased
dramatically in the last two decades.2 Whereas it is
important to manage antenatal depression, as it may confer
harmful effects if left untreated,3,4 there is conflicting
evidence for the safety of antidepressant use during early
pregnancy, particularly for congenital anomaly risks.5,6
Following drug company warnings in 2005 about paroxe-
tine-associated cardiac malformations, based on extremely
limited evidence,7 there was an increase in studies assessing
the potential teratogenicity of antidepressants, with almost
all focusing on SSRIs.8–31 The results, mostly from Euro-
pean and North American countries, have been extremely
mixed,6 with some showing similar excess congenital
anomaly risks for other SSRIs, including fluoxetine,
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sertraline, and citalopram,14,19,22,24,26,27,29 and evidence of
no increased risks with paroxetine.
Despite these inconsistencies, specific warnings against
paroxetine use in pregnancy have been incorporated into
some current national guidelines,32–34 which may inappro-
priately infer the relative safety of other SSRIs and antide-
pressant classes, and disqualify the potential risk
contribution of women’s underlying mental illness and phys-
ical health. In fact, few studies have been large enough to
assess risks of specific anatomical subgroups with individual
SSRIs. Despite the continued use of TCAs by a significant
proportion of pregnant women,35 estimates of the relative
harm of TCAs are also lacking, with only five published
studies reporting results for some selected system-specific
anomalies.12,25,29,30,36 A Danish study assessed potential con-
founding by underlying depression by comparing women
exposed to SSRIs with women who paused their use of SSRIs
during pregnancy;29 however, no studies have assessed diag-
nosed but unmedicated depression, which accounts for a
much larger proportion of women potentially at risk.4,35
Despite many women discontinuing antidepressants in
pregnancy,37 the UK has one of the highest proportions of
pregnant women internationally being prescribed antide-
pressants, yet there remain no population-based studies
assessing the teratogenicity of individual antidepressant
drugs. To inform treatment guidelines in pregnancy, we
conducted a cohort study using primary care data from a
representative national UK population to: (1) provide esti-
mates of absolute and relative risks of congenital anomaly
and system-specific anomalies in children born to women
without depression, with unmedicated depression during
the first trimester of pregnancy, and with SSRIs or TCAs in
the first trimester; (2) estimate drug class-related risks for
individual heart anomalies; and (3) estimate system-specific
congenital anomaly risks for individual SSRIs.
Methods
Study population
We studied all singleton live births for women aged 15–
45 years between 1990 and 2009 from The Health
Improvement Network (THIN), in which the medical
records of the mothers and the children were linked to
provide prospectively recorded information throughout
pregnancy and in the year before pregnancy. THIN is a
nationally representative database of computerised primary
care records from across the UK that has been validated
for pharmacoepidemiology studies, and contains diagnoses,
events, symptoms, and drug prescriptions.38 We excluded
9096 children (2.5% of the study population) whose moth-
ers had bipolar disorder, schizophrenia, other serious
psychotic disorders, or prescriptions for antimanic and
antipsychotic drugs before childbirth.
Defining all major and system-specific congenital
anomalies
All diagnoses of major congenital anomalies (MCAs) were
identified in the children’s medical records using Read
codes that we classified into 14 system-specific groups
according to the European Surveillance of Congenital
Anomalies (EUROCAT) subgroups,39 which are based on
the codes listed in the tenth edition of the International
Classification of Diseases (ICD–10, mainly in chapter Q). A
comparison of prevalence estimates across all system-spe-
cific groups (and specific MCA diagnoses for the most pre-
valent system-specific subgroups, accounting for 77% of all
MCAs) between THIN and the UK registers of the EURO-
CAT network has shown that THIN is a valid and com-
plete source of data to investigate MCAs in liveborn
children.40 We excluded 284 children with records of
genetic anomalies or anomalies attributed to known terato-
gens (e.g. Read codes for anomalies arising from maternal
infections or fetal alcohol syndrome).
In addition to system-specific subgroups, we assessed
specific types of major heart anomaly to enable the
direct comparison of our study with previous literature
and grouped the heart anomalies as follows (code lists
available from authors): septal defects [including atrial
septal defect (ASD), ventricular septal defect (VSD), and
atrioventricular septal defect (AVSD)], right ventricular
outflow tract defects (RVOTDs), left ventricular outflow
tract defects (LVOTDs), and others (including transposi-
tion off great vessels, total anomalous pulmonary venous
connection, coarctation of the aorta, Ebstein’s anomaly,
tricuspid atresia and stenosis, patent ductus arterosis
(PDA), single ventricle, tetralogy of Fallot, and truncus
arteriosus).27
Defining maternal exposure
Clinically recognised maternal depression was defined as
diagnoses of depression during the year before conception
or in the first trimester. Antenatal exposure to SSRIs and
TCAs during the first trimester of pregnancy was defined
according to the presence or absence of relevant drug pre-
scriptions in women’s records from 4 weeks before to
12 weeks after the first day of the estimated last menstrual
period. Using 4 weeks before the last menstrual period
enabled the inclusion of drug prescriptions received imme-
diately before pregnancy and potentially used during early
pregnancy. We then grouped children into five mutually
exclusive exposure groups: no clinical records of maternal
depression; maternal depression in the year before concep-
tion to the end of the first trimester, but with no antide-
pressants in the first trimester (unmedicated depression);
first-trimester exposure to SSRIs alone; first-trimester expo-
sure to TCAs alone; and dual exposure to both SSRIs and
TCAs in the first trimester.
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Statistical analyses
To estimate the disease burden of MCAs overall, and each
system-specific subgroup, we calculated absolute risks (per
10 000 live births) for the whole study population and for
children in each of the five defined antenatal exposure
groups. As SSRIs were the most commonly prescribed
antidepressants in the study population, absolute risks were
estimated for women prescribed each individual SSRI drug
alone (fluoxetine, citalopram, paroxetine, sertraline, and
escitalopram), apart from fluvoxamine, which was only
prescribed exclusively to 22 women. Children born to
women prescribed more than one type of SSRI (236 women)
were excluded from the analyses for individual SSRIs.
Logistic regression was used to estimate odds ratios (ORs)
with 95% confidence intervals (95% CIs) for MCA overall,
and for each system-specific subgroup associated with
unmedicated maternal depression, each class of antidepres-
sants, and individual SSRIs during the first trimester of preg-
nancy. We primarily used children whose mothers did not
have clinically recognised depression as the baseline group
for all comparisons, so that our results were comparable with
the published literature, so that the size of the risk estimates
for diagnosed unmedicated depression could be directly
compared with those for antidepressant drug exposures, and
to maximise the statistical power. Secondly, to assess whether
antidepressants were associated with an excess risk of MCA
compared with unmedicated depression, we conducted an
analysis using children whose mothers had unmedicated
depression as the baseline group to estimate ORs for MCAs
overall, and the three most common system-specific groups,
heart, limb, and genital anomalies, associated with each class
of antidepressant and individual SSRIs during the first tri-
mester of pregnancy.
Multivariable analyses were used to adjust all models for
maternal characteristics that had been prospectively
recorded in women’s records before delivery. These were:
maternal age; whether women had smoked before or dur-
ing pregnancy; body mass index (BMI, kg/m2), recorded
before pregnancy; and socio-economic deprivation, mea-
sured using quintiles of the Townsend Index of Depriva-
tion.41 As depression is often comorbid with other chronic
medical conditions that could be associated with increased
risks of congenital anomalies in offspring, we also adjusted
for maternal diabetes, hypertension, asthma, and epilepsy
in the year before conception or during pregnancy. Missing
values for co-variables were fitted as a separate category in
the analyses. The generalised estimating equation approach
with exchangeable correlation structure was applied to take
account of potential clustering between children born to
the same woman in consecutive pregnancies.
Studies that compare risk across several drug types in one
population can result in spurious associations because of the
high number of multiple comparison tests, and this is com-
monly amplified in congenital anomaly research because of
the need to assess the specificity of risk with individual
anomalies. Although we recognise statistically significant P
values may therefore result by chance alone, previous pub-
lished studies on antidepressant teratogenicity from other
countries used 95% CIs,14,16,22,24,25,27 so we did not carry out
specific adjustment for multiple comparisons to ensure our
findings could be directly comparable. Furthermore, statisti-
cal adjustment for multiple comparison tests assume that
there is one overall null hypothesis, and thus one research
question, whereas our aim was to assess multiple drugs
across several types of anatomical groups, as a key objective
was to assess whether there were different specific drug–
anomaly associations. Multiple comparisons are thus often
inevitable in congenital anomaly research; however, for all
adjusted ORs we described the exact numbers of exposed
cases available, and for associations where 95% CIs did not
cross 1.00, we additionally presented exact P values to three
decimal places in consideration that we would expect smaller
values of P < 0.01 to be less likely as a result of chance alone.
All analyses were carried out using STATA SE 11.0 (Stata
Corp., College Station, TX, USA).
Results
Among 349 127 liveborn singletons, the overall prevalence
of MCA was 2.7% (95% CI 2.6–2.8%). For children with
MCA, their mothers had a similar sociodemographic
profile to mothers of children without MCA (Table 1);
however, higher proportions of mothers of children with
MCA had chronic medical comorbidities, particularly
diabetes and epilepsy, than those of children with no MCA.
Of all children, 3.8% had mothers with depression that was
not treated with antidepressant medication during the first
trimester (diagnosed but unmedicated depression), whereas
2.2 and 0.7% had mothers with first-trimester exposure to
SSRIs alone and TCAs alone, respectively. The most com-
monly prescribed SSRIs during the first trimester of preg-
nancy were fluoxetine (0.9%), citalopram (0.6%), and
paroxetine (0.3%). Maternal characteristics for pregnancies
in women with unmedicated depression or antidepressant
use showed higher socio-economic deprivation, smoking,
obesity, and asthma, compared with pregnancies in women
with no depression (Table S1). In particular, women with
medicated depression were slightly more likely to have
pre-existing diabetes, hypertension, and epilepsy than
women with unmedicated depression; however, distribu-
tions were similar across antidepressant classes and individ-
ual SSRIs (Tables S1 and S2).
Table 2 shows the numbers and absolute risks of any
MCA and system-specific anomalies for children with
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different antenatal exposures, and Table 3 shows adjusted
ORs (aORs). Children born to women with diagnosed
depression unmedicated in early pregnancy had higher
absolute risks of MCAs than children of mothers with no
depression (283/10 000 and 268/10 000, respectively;
Table 2), although the relative risk was not statistically
significant (aOR 1.07, 95% CI 0.96–1.18; Table 3).
Similarly, there were no increased risks of MCA overall
associated with SSRIs, TCAs, or joint exposure.
With few exceptions, the absolute risks of system-specific
congenital anomalies were similar for children across the dif-
ferent antenatal exposure groups, showing no substantial
increases compared with children born to women without
depression. Absolute risks of heart anomalies were higher in
children born to women with unmedicated depression and
in children exposed to SSRIs or TCAs in early pregnancy,
compared with children of mothers with no depression
(Table 2); however, the aORs ranged between 1.03 and 1.14,
and none were statistically significant (Table 3). Similarly,
results for other system-specific anomaly groups were not
statistically significant, apart from a two-fold increased risk
of ear, face, and neck anomalies in children born to women
with diagnosed depression unmedicated in the first trimester
(aOR 2.39, 95% CI 1.08–5.27, P = 0.031) and an increase of
nervous system anomalies in children with joint SSRI and
TCA exposure in the first trimester (aOR 4.57, 95% CI 1.10–
19.06, P = 0.037; Table 3). When examining specific types
of heart anomaly, there were again no statistically significant
increased risks for children born to women with unmedi-
cated depression in the first trimester or for children
exposed to SSRIs or TCAs, compared with children of
women with no depression (Table 4).
Compared with an absolute risk of 268/10 000 children
whose mothers had no depression and 283/10 000 children
whose mothers had unmedicated depression, absolute risks
of overall MCAs were lower for children exposed to fluoxe-
tine, citalopram, or escitalopram in early pregnancy (241,
267 and 210/10 000, respectively), but higher for children
exposed to paroxetine or sertraline (300 and 330/10 000,
respectively) (Table 5). For heart anomalies, compared with
absolute risks of 75/10 000 children whose mothers had no
depression and 83/10 000 children whose mothers had
unmedicated depression, paroxetine and sertraline had the
highest absolute risks (142 and 119/10 000, respectively),
followed by escitalopram (90/10 000) and citalopram (87/
10 000), whereas fluoxetine showed a lower risk (66/
10 000). There was wide variation in adjusted odds ratios
for MCA overall and for system-specific subgroups associ-
ated with each SSRI drug: some were above and others
below 1.00, and many 95% CIs were wide (Table 5). A
78% increase in congenital heart anomalies was found
among children with paroxetine exposure alone (aOR 1.78,
Table 1. Maternal characteristics for singletons born with and without major congenital anomalies
All children Children without MCAs Children with MCAs
n = 349 127 n = 339 730 n = 9397
n % n % n %
Maternal age at the end of pregnancy,
years (Median [interquartile range])
30 (26–34) 30 (26–34) 30 (26–34)
Townsend deprivation index
1 (least deprived) 85 160 24.4 82 850 24.4 2310 24.6
2 67 968 19.5 66 193 19.5 1775 18.9
3 68 224 19.5 66 368 19.5 1856 19.8
4 63 284 18.1 61 596 18.1 1688 18.0
5 (most deprived) 47 190 13.5 45 850 13.5 1340 14.3
Missing 17 301 5.0 16 873 5.0 428 4.6
Ever smoked before delivery 132 934 38.1 129 415 38.1 3519 37.4
BMI before pregnancy (kg/m2)
Underweight (<18.5) 11 335 3.2 11 026 3.2 309 3.3
Normal (18.5–24.9) 154 140 44.2 150 128 44.2 4012 42.7
Overweight (25–29.9) 58 998 16.9 57 407 16.9 1591 16.9
Obese (30–39.9) 32 130 9.2 31 154 9.2 976 10.4
Missing 92 524 26.5 90 015 26.5 2509 26.7
Diabetes 1619 0.5 1521 0.4 98 1.0
Hypertension 919 0.3 877 0.3 42 0.4
Asthma 26 981 7.7 26 204 7.7 777 8.3
Epilepsy 1431 0.4 1353 0.4 78 0.8
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95% CI 1.09–2.88, P = 0.020). This was based on 17
affected children among the 1200 exposed to paroxetine
who had a range of heart anomalies [eight with septal
defects (three with ASD, four with VSD, one with AVSD),
one with ASD and PDA, four with PDA, one with RVOTD
(pulmonary infundibular stenosis), one with transposition
of the great vessels, and two with unspecified heart anoma-
lies]. Despite the higher absolute risks of overall MCA and
heart anomalies in children of mothers prescribed with
sertraline, the aORs were not statistically significant (aOR
1.27, 95% CI 0.85–1.89; aOR 1.52, 95% CI 0.78–2.96,
respectively). There were also statistically significant
increased risks of urinary and digestive system anomalies
associated with citalopram exposure (P = 0.025 and 0.035,
respectively), based on ten and five cases, respectively,
among the 1946 children with citalopram exposure
(Table 5). We also found an increased risk of respiratory
system anomalies associated with sertraline (aOR 4.04, 95%
CI 1.00–16.27, P = 0.049), based on five exposed cases, and
a decreased risk of genital system anomalies with fluoxetine
exposure (aOR 0.38, 95% CI 0.16–0.93, P = 0.034), based
on five exposed cases (Table 5).
When we used women with diagnosed but unmedicated
depression as the baseline group (Table 6), most point
estimates of aORs associated with SSRIs, TCAs, and indi-
vidual SSRI drugs decreased slightly. No statistically signifi-
cant associations of overall and system-specific congenital
anomaly risks were found, apart from a decreased risk of
genital system anomaly with SSRI exposure, and specifically
fluoxetine exposure (aOR 0.31, 95% CI 0.12–0.76,
P = 0.024); however, slightly higher point estimates of con-
genital anomaly risk in children exposed to paroxetine and
sertraline remained in comparison with children of mothers
with unmedicated depression (Table 6). The aORs for con-
genital heart anomalies in children exposed to paroxetine
and sertraline were 1.67 (95% CI 1.00–2.80, P = 0.051) and
1.39 (95% CI 0.70–2.74, P = 0.345), respectively, which
were similar to the previous estimates compared with chil-
dren born to women without diagnosed depression
(Tables 5 and 6).
Discussion
Main findings
Overall, MCA and system-specific anomaly risks were similar
in children of mothers with and without antidepressants
(SSRIs or TCAs) in early pregnancy. For individual SSRIs,
we found no evidence of teratogenicity for most
antidepressants, except for an increase in heart anomalies
associated with paroxetine and an excess risk of similar mag-
Table 2. Absolute risks (per 10 000 live births) of major congenital anomalies in children according to first-trimester exposure to unmedicated
depression and antidepressant medications
All children No depression Depression* SSRIs alone TCAs alone SSRIs &
TCAs**
n = 349 127 n = 325 294 n = 13 432 n = 7683 n = 2428 n = 290
n n/10 000 n n/10 000 n n/10 000 n n/10 000 n n/10 000 n n/10 000
All MCAs combined 9397 269 8731 268 380 283 204 266 74 305 8 276
Heart 2646 76 2444 75 112 83 68 89 20 82 2 69
Limb 1868 54 1750 54 71 53 33 43 14 58 0 0
Genital system 1391 40 1292 40 67 50 22 29 8 33 2 69
Urinary system 886 25 815 25 37 28 23 30 9 37 2 69
Chromosomal 592 17 551 17 27 20 10 13 4 16 0 0
Orofacial cleft 472 14 438 13 21 16 11 14 2 8 0 0
Nervous system 513 15 465 14 24 18 15 20 7 29 2 69
Musculoskeletal system 468 13 442 14 14 10 9 12 2 8 1 34
Digestive system 338 10 313 10 11 8 11 14 3 12 0 0
Eye 332 10 313 10 9 7 6 8 4 16 0 0
Other anomalies*** 328 9 305 9 14 10 7 9 2 8 0 0
Respiratory system 222 6 205 6 5 4 8 10 4 16 0 0
Ear, face, and neck 90 3 83 3 7 5 0 0 0 0 0 0
Abdominal wall 74 2 69 2 2 1 3 4 0 0 0 0
*Diagnosed in the mother in the year before conception up to the end of the first trimester, but with no antidepressant drug prescriptions in the
first trimester.
**Dual exposure to both drug classes in the first trimester of pregnancy.
***For example, asplenia, situs inversus, and skin disorders.
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Table 3. Adjusted odds ratios for major congenital anomalies in children with first-trimester exposure to unmedicated maternal depression and
antidepressant medications (n = 349 127 children, 9397 with major congenital anomalies)
Depression* SSRIs alone TCAs alone SSRIs & TCAs**
n = 13 432 n = 7683 n = 2428 n = 290
aOR*** 95% CI aOR*** 95% CI aOR*** 95% CI aOR*** 95% CI
All MCAs combined 1.07 0.96–1.18 1.01 0.88–1.17 1.09 0.87–1.38 1.02 0.50–2.06
Heart 1.10 0.91–1.33 1.14 0.89–1.45 1.03 0.65–1.63 0.85 0.21–3.42
Limb 1.03 0.81–1.31 0.88 0.62–1.25 1.04 0.61–1.77 –
Genital system 1.25 0.98–1.60 0.71 0.46–1.08 0.81 0.41–1.63 1.67 0.41–6.79
Urinary system 1.10 0.79–1.54 1.20 0.79–1.82 1.46 0.76–2.83 2.75 0.68–11.05
Chromosomal 1.29 0.87–1.93 0.79 0.42–1.48 0.90 0.34–2.43 –
Orofacial cleft 1.13 0.73–1.75 1.06 0.58–1.93 0.58 0.14–2.31 –
Nervous system 1.23 0.81–1.86 1.39 0.82–2.34 1.86 0.88–3.92 4.57 1.10–19.06*****
Musculoskeletal system 0.78 0.46–1.33 0.91 0.44–1.88 0.56 0.14–2.33 2.66 0.39–18.10
Digestive system 0.84 0.46–1.54 1.43 0.79–2.61 1.26 0.40–3.94 –
Eye 0.70 0.36–1.38 0.82 0.36–1.86 1.68 0.63–4.50 –
Other anomalies**** 1.21 0.69–2.13 1.30 0.61–2.77 0.83 0.19–3.58 –
Respiratory system 0.57 0.23–1.38 1.56 0.77–3.15 2.50 0.93–6.69 –
Ear, face, and neck 2.39 1.08–5.27****** – – –
Abdominal wall 0.53 0.13–2.17 1.41 0.43–4.59 – –
*Diagnosed in the mother in the year before conception up to the end of the first trimester, but with no antidepressant drug prescriptions.
**Dual exposure to both drug classes in the first trimester of pregnancy.
***Odds ratio compared with children born to mothers without clinically recognised depression, adjusted for maternal age at the end of
pregnancy, year of childbirth, Townsend deprivation quintile, maternal smoking history, body mass index before pregnancy, and maternal
diabetes, hypertension, asthma, and epilepsy in the year before conception or during pregnancy.
****For example, asplenia, situs inversus, and skin disorders.
*****P = 0.037.
******P = 0.031.
Table 4. Absolute risks (per 10 000 live births) and adjusted odds ratios for specific heart anomalies in children with first-trimester exposure to
unmedicated maternal depression and antidepressant medications (n = 349 127 children, 2646 with heart anomalies)
MCAs No depression Depression* SSRIs alone TCAs alone
n = 325 294 n = 13 432 n = 7683 n = 2428
n/10 000 n/10 000 aOR (95% CI)** n/10 000 aOR (95% CI)** n/10 000 aOR (95% CI)**
Heart
Septal defect*** 47 51 1.09 (0.86–1.39) 43 0.89 (0.63–1.27) 49 0.98 (0.55–1.73)
ASD 10 9 0.85 (0.48–1.51) 18 1.68 (0.98–2.91) 16 1.43 (0.54–3.83)
VSD 33 36 1.09 (0.81–1.45) 21 0.63 (0.38–1.03) 33 0.93 (0.46–1.87)
RVOTD 3 5 1.58 (0.73–3.40) 8 2.22 (0.98–5.03) 4 1.19 (0.17–8.23)
LVOTD 1 1 1.59 (0.36–7.16) 1 1.50 (0.20–11.24) 4 4.72 (0.63–35.25)
Other**** 33 40 1.20 (0.90–1.58) 44 1.27 (0.90–1.80) 33 0.94 (0.43–2.04)
*Diagnosed in the mother in the year before conception up to the end of the first trimester, but with no antidepressant drug prescriptions.
**Odds ratio compared with children born to mothers without clinically recognised depression, adjusted for maternal age at the end of
pregnancy, year of childbirth, Townsend deprivation quintile, maternal smoking history, body mass index before pregnancy, and maternal
diabetes, hypertension, asthma, and epilepsy in the year before conception or during pregnancy.
***Atrial, ventricular, or combined septal defects.
****Transposition of great vessels, total anomalous pulmonary venous connection, coarctation of the aorta, Ebstein’s anomaly, tricuspid atresia
and stenosis, patent ductus arterosis, single ventricle, tetralogy of Fallot, truncus arteriosus.
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nitude (though not statistically significant) with sertraline.
Most heart anomalies in children exposed to paroxetine were
relatively mild conditions, with no evidence that exposure was
related to a specific type of heart anomaly. Citalopram was
associated with increased urinary and digestive anomalies;
however, these were based on fewer exposed cases.
Strengths and limitations
Our study is among few that have examined the relative
safety across antidepressant classes, and is the first UK study
to assess individual SSRIs with system-specific anomalies in a
single population. With over 2400 TCA exposures, 7600 SSRI
exposures, and over 13 000 mothers with diagnosed unmedi-
cated depression, the statistical power was greater or similar
to previous population-based studies from Europe and
North America.22,24–27,29–31 Power was inevitably reduced
when examining system-specific groups, and given the num-
ber of comparisons conducted, we cannot rule out random
error, which is also a limitation of previous studies.
We included MCAs diagnosed up to age 20 years, where
available, so we expect to have captured these for live
births as completely if not more completely than registry
data.40 As stillborn children are not registered with a gen-
eral practice (GP) we only included liveborn children, as in
most previous studies. Stillbirth occurs in approximately
0.6% of births in developed countries,42 and congenital
anomalies account for only 8–14% of stillbirths,43,44 so the
effect of excluding them on our estimates should be mini-
mal. We were also unable to ascertain MCAs among preg-
nancies ending in spontaneous or induced abortions, which
may underestimate teratogenicity, a limitation that no
studies have overcome. There are no accurate data sources
to ascertain congenital anomalies in pregnancies than end
in spontaneous abortion because many occur early in gesta-
tion when women may not know they are pregnant, and
autopsy information on later losses is rarely ascertained.
This is similar for induced abortions, as most are carried
out early in pregnancy. UK registry ascertainment of MCAs
among medically terminated pregnancies varies regionally,45
and national abortion statistics estimate <1% are because
of an MCA.46 In the same primary care population used in
this study, we found women exposed to SSRIs or TCAs
had increased risks of both spontaneous and induced abor-
tion; women continuing SSRI or TCA treatment when
pregnant had higher risks than women who discontinued,
particularly those on SSRIs.35 A lack of information on the
reasons for these spontaneous and induced abortions, and
potential confounding by changes in severity of the under-
lying depression, limit our ability to determine whether
these were teratogenic effects.
The prevalence of diagnosed maternal depression in UK
primary care is similar to estimates from surveys using
clinical diagnostic criteria.47 This enabled us to assess
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effects of underlying maternal depression on MCA risks in
offspring, and to compare risks between women with medi-
cated and unmedicated depression, which has not been
achieved previously. Although the effects of psychotropic
drugs can never be completely separated from more severe
illness itself, such estimates are less likely to be influenced
by residual confounding effects, as when comparing with
women not suffering from depression. Moreover, as all
pregnant women in the UK must be registered with a GP
to benefit from free antenatal care and prescriptions, it is
unlikely that women with psychotropic drug prescriptions
were not identified. Women receiving prescriptions may
not have actually taken the medication during the organo-
genetic period, which could bias estimates towards a null
effect; however, studies large enough to assess congenital
anomaly risks are limited in their ability to obtain data on
actual medication consumption.
Exposure, outcome, and covariate data were prospec-
tively recorded, thereby minimising recall bias. Maternal
sociodemographics and comorbidities were included in the
statistical models to minimise confounding; however, mis-
classification of some covariables was possible if not
recorded in a timely manner in the GP records.
Interpretation
To our knowledge, no studies have assessed congenital
anomaly risks in women with clinically diagnosed depres-
sion who were not prescribed antidepressants in early preg-
nancy. A Danish study found an increased heart anomaly
risk in children of 806 women treated with SSRIs immedi-
ately before and after, but not during, pregnancy, which
was similar to the increased risk in 4183 women exposed
to SSRIs in pregnancy.29 Confounding by indication may
therefore contribute to drug-associated risks, but 806
women (0.1% of the overall population of 848 786 women)
would not have accounted for the majority of women with
unmedicated depression.
Five studies have examined the comparative safety of
SSRIs and TCAs in a single population.12,25,29,30,36 A UK
GP data study of approximately 3000 pregnancies exposed
to antidepressants assessed only class-level effects, and
found no MCA risks; however, their inclusion of stillbirths
and terminations probably distorted the true risks, as con-
genital anomalies are rarely recorded for these pregnancies
in GP data.30 Two Swedish studies have found that heart
anomalies were associated with paroxetine exposure (OR
1.66, 95% CI 1.09–2.53, based on 24 exposed cases), but
not with SSRIs overall, which is consistent with our find-
ings.25,36 They also found a similar TCA-associated risk
(OR 1.63, 95% CI 1.12–2.36).25 In a USA study, limb
anomalies and spina bifida were associated with TCAs.12
Although we did not find overall MCA increases with
TCAs, we found an increase of nervous system anomalies
in children with dual TCA and SSRI exposure. These risks
(including the one in our study) were based on between
one and eight exposed cases only, and have not been con-
sistently reported in other studies.
A US case–control study including more than 300 MCA
cases with first-trimester SSRI exposure found increases of
RVOTD associated with paroxetine (OR 3.3, 95% 1.3–8.8),
and increases of septal defect associated with sertraline
(OR 2.0, 95% CI 1.2–4.0).14 Similar increases of heart
anomalies with paroxetine and sertraline were found in
other studies from the USA, Denmark, and Fin-
land.16,22,24,27 The consistency of a modest increase of heart
anomalies with paroxetine and sertraline is reassuring for
the validity of our results. Results for other individual
SSRIs are inconsistent. The Finish study also reported asso-
ciations between RVOTD and fluoxetine (OR 2.0, 95% CI
1.3–3.2) and between neural tube defects and citalopram
(OR 2.5, 95% CI 1.2–5.1).27 In contrast, the Danish study
reported a nearly three-fold increase of septal defect with
citalopram (OR 2.5, 95% 1.0–6.1), but not with fluoxetine
(OR 1.3, 95% CI 95% 0.3–5.4),22 and later re-analysis
showed small increases for some heart anomalies for all
individual SSRIs, apart from escitalopram.29 As heart
anomalies are by far the most common MCA, the power to
detect risks for other system-specific groups is limited
across all published studies. Nevertheless, as drug-specific
effects for non-cardiovascular anomalies have been largely
inconsistent in the existing literature, there is no strong
evidence that any individual SSRIs increase their risk.
Conclusion
Children whose mothers were prescribed SSRIs or tricyclic
antidepressants (TCAs) in early pregnancy were not at an
increased risk of major congenital anomaly overall, nor were
children whose mothers had diagnosed but unmedicated
depression. We provide absolute and relative major conge-
nital anomaly (MCA) risks for individual antidepressants to
facilitate health professionals’ discussions of the potential
risks and benefits of treated and untreated depression with
pregnant women, or with those planning to conceive. For
example, where approximately eight children out of 1000
born to women without depression are expected to have
congenital heart anomalies, approximately seven additional
cases could occur if children were exposed to paroxetine.
Children born to women with medicated and unmedi-
cated depression have, overall, similar risks of having
MCAs as those born to women without depression. Our
findings, together with findings from other studies, how-
ever, indicate that children born to women prescribed par-
oxetine have a small excess risk of congenital heart
anomalies, although most have relatively mild conditions.
Although this may indicate real teratogenicity, most studies
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were conducted after the specific pharmaceutical warning
against paroxetine in 2005,7 so increased international con-
cerns of its potential risks may have led to increased moni-
toring and early diagnosis in children exposed to
antidepressants, particularly SSRIs. Evidence to disfavour
certain SSRIs regarding teratogenicity remains weak, and all
seem largely safe in terms of MCA risks.
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